awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34251223-1705D2FD-E322-4DB3-A33F-D5A98E49B2A7
Q34251223-1705D2FD-E322-4DB3-A33F-D5A98E49B2A7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34251223-1705D2FD-E322-4DB3-A33F-D5A98E49B2A7
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
P2860
Q34251223-1705D2FD-E322-4DB3-A33F-D5A98E49B2A7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34251223-1705D2FD-E322-4DB3-A33F-D5A98E49B2A7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
21b05911c495043580179e4a6bfa7859c4a847fa
P2860
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.